Drug resistance in acute leukaemia and reversion

Turkish Journal of Medical Sciences

Volumn 33, Issue 5, 2003, Pages 271-279

  Marie, Jean Pierre ^a   Legrand, Ollivier ^a  

^a SORBONNE UNIVERSITÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ACRIDINE DERIVATIVE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTHRANILIC ACID DERIVATIVE; BIRICODAR; CD34 ANTIGEN; CD7 ANTIGEN; CYCLOSPORIN A; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GG 120918; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; OBLIMERSEN; PROTEIN BAX; PROTEIN BCL 2; TARIQUIDAR; TIPIFARNIB; UNCLASSIFIED DRUG; VALSPODAR; ZOSUQUIDAR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; DRUG TOXICITY; HUMAN; MULTIDRUG RESISTANCE; PROTEIN EXPRESSION; REVIEW;

EID: 0141782442     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Goldie J, Coldman A. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Res 63: 1727-31. 1979.
2. Veerman A, Pieters R. Drug sensitivity assays in leukemia and lymphoma. Br J Haematol 74: 381-4, 1990.
3. Delmer A, Marie J, Thevenin D et al. Multivariate analysis of prognostic factors in acute myeloid leukemia: value of clonogenic leukemic cell properties. J Clin Oncol 7: 738-46, 1989.
4. Pieters R, Huismans D, Loonen A et al. Relation of cellular drug resistance to long term clinical outcome in childhood acute lymphoblastic leukemia. Lancet 338: 399-403, 1991.
5. Zimm S, Collins J, Riccarrdi R et al. Variable bioavailability of oral mercaptopurine: Is maintenance chemotherapy in acute lymphoblastic leukemia being optimally delivered? N Engl J Med 308: 1005-9, 1983.
6. Padro T, Ruiz S, Bieker R et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95: 2637-44, 2000.
7. Biedler J, Riehm H. Cellular resistance to actinomycin D in Chinese hamster in vitro: cross resistance, radioautographic and cytogenetic studies. Cancer Res 30: 1174-80, 1970.
8. Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim Biophys Acta. 1461: 237-62, 1999.
9. Borst P, Evers R, Kool M et al. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295-302, 2000.
10. Gros P, Fallows D, Croop J et al. Chromosome-mediated gene transfer of multidrug resistance. Mol Cell Biol 6: 3785-90, 1986.
11. Grant C, Valdimarsson G, Hipfner D et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54: 357-61, 1994.
12. Litman T, Brangi M, Hudson E et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). J Cell Sci 113: 2011-21, 2000.
13. Litman T, Druley TE, Stein WD et al. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931-59, 2001.
14. Beck W, Grogan T, Willman C et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 56: 3010-20, 1996.
15. Marie J, Huet S, Faussat A et al. Multicentric evaluation of the MDR phenotype in leukemia. Leukemia 11: 1086-94, 1997.
16. Marie J, Zhou D, Gurbuxani S et al. MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer 32A: 1034-8, 1996.
17. Leith CP, Kopecky KJ, Chen IM et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94: 1086-99, 1999.
18. Paietta E, Andersen J, Racevskis J et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia. 8: 968-73, 1994.
19. Sonneveld P, Van Dongen J, Hagemeijer A et al. High expression of multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia 7: 963-9. 1993.
20. Broxterman H, Giaccone G, Lankelma J et al. Multidrug resistance proteins and other drug transport-related resistance to natural product agents. Curr Opin Oncol 7: 532-40, 1995.
21. Legrand O, Simonin G, Beauchamp-Nicoud A et al. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood 94: 1046-56, 1999.
22. van der Kolk DM, de Vries EG, Noordhoek L et al. Activity and expression of the multidrug resistance proteins P-glycoprotein, MRP1, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia 15: 1544-53, 2001.
23. Abbott BL, Colapietro AM, Barnes Y et al. Low levels of ABCG2 expression in adult AML blast samples. Blood 100: 4594-601, 2002.
24. Ross DD, Karp JE, Chen TT et al. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood 96: 365-368, 2000.
25. van der Kolk DM, Vellenga E, Scheffer GL et al. Expression and activity of breast cancer resistance protein (BCRP) in de novo and relapsed acute myeloid leukemia. Blood 99: 3763-70, 2002.
26. Steinbach D, Sell W, Voigt A et al. BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia 16: 1443-7, 2002.
27. Tafuri A, Petrucci MT, Gregorj C et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukaemia. Blood 100: 974-981, 2002.
28. Sauerbrey A, Sell W, Steinbach D et al. Expression of the BCRP gene (ABCG2/MXR/ABCP) in childhood acute lymphoblastic leukaemia. Br J Haematol 118: 147-50, 2002.
29. Izquierdo M, Scheffer G, Flens M et al. Major vault protein LRP-related multidrug resistance. Eur J Cancer 32A: 979-84, 1996.
30. List A, Spiers C, Grogan T et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood 87: 2464-9, 1996.
31. Legrand O, Simonin G, Zittoun R et al. Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. Leukemia 12: 1367-74, 1998.
32. Lacombe F, Belloc F, Dumain P et al. Detection of cytarabine resistance in patients with acute myelogenous leukemia using flow cytometry. Blood 84: 716-23, 1994.
33. Schuurhuis G, Broxterman H, Ossenkoppele G et al. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1: 81-93, 1995.
34. Klumper E, Ossenkoppele G, Pieters R et al. In vitro resistance to cytosine arabinoside, not to daunorubicin, is associated with the risk of relapse in de novo acute myeloid leukaemia. Br J Haematol 93: 903-10, 1996.
35. Rustum Y, Preisler H. Correlation between leukemic cell retention of cytosine arabinoside and response to therapy. Cancer Res 39: 42-9, 1979.
36. Gati W, Paterson A, Larratt L et al. Sensitivity of acute leukemia cells to cytarabine is a correlate of cellular es nucleoside transporter site content measured by flow cytometry with SAENTAfluorescein. Blood 90: 346-53, 1997.
37. Galmarini CM, Graham K, Thomas X et al. Expression of high Km 5′-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood 98: 1922-6, 2001.
38. Galmarini CM, Thomas X, Calvo F et al. In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia. Br J Haematol 117: 860-868, 2002.
39. Fisher D. Apoptosis in cancer therapy: crossing the threshold. Cell 78: 539-42, 1994.
40. Harris C. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1442-55, 1996.
41. Imamura J, Miyishi I, Koeffler H. p53 in hematologic malignancies. Blood 84: 2412-21, 1994.
42. Kohn K, Regulatory genes and drug sensitivity. J Nat Cancer Inst 88: 1255-6, 1996.
43. Reed J. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol/Oncol Clin North Am 9: 451-73, 1995.
44. Campos L, Rouault J, Sabido O et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81: 3091-6, 1993.
45. Campos L, Sabido O, Sebban C et al. Expression of BCL-2 protooncogene in adult acute lymphoblastic leukemia. Leukemia 10: 434-8, 1996.
46. DelPoeta G, Venditti A, Del Principe MI et al. Amount of spontaneous apoptosis detected by bax/bcl-2 ration predicts outcome in acute myeloid leukaemia. Blood 101: 2125-2131, 2003.
47. Prokop A, Wieder T, Sturm I et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia 14: 1606-13, 2000.
48. Dias S, Choy M, Alitalo K, et al. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 99: 2179-84, 2002.
49. Robert J. Multidrug resistance in oncology: diagnostic and therapeutic approaches. Eur J Clin Invest 29: 536-45, 1999.
50. Solary E, Witz B, Caillot D et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicentric study. Blood 88: 1198-205, 1996.
51. Solary E, Drenou B, Campos L et al. Quinine as a multidrug resistance inhibitor: a phase III multicentric randomized study in adult de novo acute myelogenous leukaemia. Blood 27 March 2003 (Epub ahead of print).
52. Baer MR, George SL, Dodge RK et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood 100: 1224-32, 2002.
53. List AF, Kopecky KJ, Willman CL et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98: 3212-20, 2001.
54. List AF, Kopecky KJ, Willman CL et al. Cyclosporine inhibition of P-glycoprotein in chronic myeloid leukemia blast phase. Blood 100: 1910-2, 2002.
55. Dantzig AH, Law KL, Cao J et al. Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr Med Chem 8: 39-50, 2001.
56. Mistry P, Stewart AJ, Dangerfield W et al. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61: 749-58, 2001.
57. Maliepaard M, van Gastelen MA, Tohdo A et al. Circumvention of breast cancer resitance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918. Clin Cancer Res 7: 935-941, 2001.
58. Peck RA, Hewett J, Harding MW et al. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin. J Clin Oncol 19: 3130-41, 2001.
59. Plunkett W, Gandhi V, Grunewald R et al. Pharmacologically directed design of AML therapy. In: Acute Myelogenous Leukemia: Progress and Controversies (Gale RP, ed.). New York: Wiley-Liss, 1990: pp 481-92.
60. Terpstra W, Löwenberg B. Application of myeloid growth factors in the treatment of acute myeloid leukemia. Leukemia 11: 315-27, 1997.
61. Karp JE, Lancet JE, Kaukmann SH et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97: 3361-3369, 2001.
62. Waters JS, Webb A, Cunningham D et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 18: 181-223, 2000.
63. Marcucci G, Byrd JC, Dai G et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101: 425-32, 2003.